Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Canada allows Pfizer COVID-19 vaccine for children aged 12-15

Published 05/05/2021, 10:39 AM
Updated 05/05/2021, 06:21 PM
© Reuters. FILE PHOTO: Empty vials of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at The Michener Institute, in Toronto, Canada January 4, 2021. REUTERS/Carlos Osorio

© Reuters. FILE PHOTO: Empty vials of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at The Michener Institute, in Toronto, Canada January 4, 2021. REUTERS/Carlos Osorio

(Corrects headline and lead to make clear that Canada was not the first nation as stated by Canadian officials, adds context from Pfizer in fourth paragraph)

By David Ljunggren

OTTAWA (Reuters) -Canada is authorizing the use of Pfizer Inc (NYSE:PFE)'s COVID-19 vaccine for use in children aged 12 to 15, the first doses to be allowed in the country for people that young, the federal health ministry said on Wednesday.

Supriya Sharma, a senior adviser at the Canadian federal health ministry, said the Pfizer vaccine, produced with German partner BioNTech SE (NASDAQ:BNTX), was safe and effective in the younger age group.

"We are starting to see the light at the end of the tunnel," she told reporters.

Sharma and a health ministry spokesman said Canada was the first country to grant such an approval, but a Canadian representative for Pfizer later said Algeria permitted use of the vaccine for this age group in April. The Canadian health ministry said it had no information about the discrepancy.

The U.S. Food and Drug Administration is expected to take a similar step "very soon," U.S. health officials said.

Separately, authorities reported the third death of a Canadian from a rare blood clot condition after receiving AstraZeneca (NASDAQ:AZN) PLC's's COVID-19 vaccine. The man, who was in his sixties, lived in the Atlantic province of New Brunswick (NYSE:BC).

Jennifer Russell, the chief medical officer of health in New Brunswick, said the province would continue using the AstraZeneca vaccine. Alberta reported a death from clotting on Tuesday and Quebec announced one on April 27.

"There will be rare cases where thrombosis will occur. However, the risks remain minimal compared to the risks, complications and potential consequences of COVID-19," Russell told reporters.

Canada's federal government has bought tens of millions of doses of vaccines but critics complain the pace of inoculation is lagging due to bottlenecks in the 10 provinces, which are responsible for administering the doses.

Alberta will become the first province to offer COVID-19 vaccines to everyone aged 12 and over from May 10, Premier Jason Kenney said on Wednesday, a day after he introduced tighter public health measures to combat a third wave of the pandemic.

© Reuters. FILE PHOTO: Empty vials of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at The Michener Institute, in Toronto, Canada January 4, 2021. REUTERS/Carlos Osorio

Alberta, home to Canada's oil patch, has the highest rate per capita of COVID-19 in the country, with nearly 24,000 active cases and 150 people in intensive care.

Around 20% of the 1,249,950 cases of COVID-19 in Canada have been reported in people under the age of 19. Canada has recorded 24,396 deaths.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.